Array Biopharma (ARRY) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $5.33 +14.87%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
KTB, CABO, FDUS, More
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $33.28 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Array Technologies Inc. (ARRY) Misses Q3 EPS by 3c ; Offers Guidance
- Steris (STE) Tops Q3 EPS by 26c ; Offers Guidance
- Amcor plc (AMCR) Misses Q1 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
